These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 34978255)
1. Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison. Schuster SJ; Zhang J; Yang H; Agarwal A; Tang W; Martinez-Prieto M; Bollu V; Kuzan D; Maziarz RT; Kersten MJ Leuk Lymphoma; 2022 Apr; 63(4):845-854. PubMed ID: 34978255 [TBL] [Abstract][Full Text] [Related]
2. Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel. Cartron G; Fox CP; Liu FF; Kostic A; Hasskarl J; Li D; Bonner A; Zhang Y; Maloney DG; Kuruvilla J Exp Hematol Oncol; 2022 Mar; 11(1):17. PubMed ID: 35337365 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States. Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan. Tsutsué S; Makita S; Asou H; Matsuda H; Yamaura R; Taylor TD Future Oncol; 2024; 20(19):1333-1349. PubMed ID: 38597742 [TBL] [Abstract][Full Text] [Related]
5. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. Maloney DG; Kuruvilla J; Liu FF; Kostic A; Kim Y; Bonner A; Zhang Y; Fox CP; Cartron G J Hematol Oncol; 2021 Sep; 14(1):140. PubMed ID: 34493319 [TBL] [Abstract][Full Text] [Related]
6. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407 [TBL] [Abstract][Full Text] [Related]
7. Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1. Salles G; Spin P; Liu FF; Garcia J; Kim Y; Hasskarl J Adv Ther; 2021 Jun; 38(6):3266-3280. PubMed ID: 33970454 [TBL] [Abstract][Full Text] [Related]
8. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies. Oluwole OO; Neelapu SS; Ray MD; Limbrick-Oldfield EH; Wade SW; Kanters S; Patel AR; Locke FL Expert Rev Anticancer Ther; 2024 Jun; 24(6):457-465. PubMed ID: 38646700 [TBL] [Abstract][Full Text] [Related]
9. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma. St-Pierre F; Gordon LI Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471 [TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care. Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867 [TBL] [Abstract][Full Text] [Related]
12. Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Makita S; Yamamoto G; Maruyama D; Asano-Mori Y; Kaji D; Ananthakrishnan R; Ogasawara K; Stepan L; Schusterbauer C; Rettby N; Hasskarl J; Izutsu K Cancer Med; 2022 Dec; 11(24):4889-4899. PubMed ID: 35619325 [TBL] [Abstract][Full Text] [Related]
13. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma. Oluwole OO; Chen JMH; Chan K; Patel AR; Jansen JP; Keeping S; Zheng Y; Snider JT; Locke FL Leuk Lymphoma; 2022 Dec; 63(13):3052-3062. PubMed ID: 36048026 [TBL] [Abstract][Full Text] [Related]
14. In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma. Ogasawara K; Lymp J; Mack T; Dell'Aringa J; Huang CP; Smith J; Peiser L; Kostic A Clin Pharmacol Ther; 2022 Jul; 112(1):81-89. PubMed ID: 35156195 [TBL] [Abstract][Full Text] [Related]
15. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Ogasawara K; Kamdar M Blood; 2023 Apr; 141(14):1675-1684. PubMed ID: 36542826 [TBL] [Abstract][Full Text] [Related]
16. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL Biol Blood Marrow Transplant; 2020 Sep; 26(9):1581-1588. PubMed ID: 32561336 [TBL] [Abstract][Full Text] [Related]
17. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy. Badaracco J; Gitlin M; Keating SJ Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529 [TBL] [Abstract][Full Text] [Related]
18. Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma. Van Le H; Van Naarden Braun K; Nowakowski GS; Sermer D; Radford J; Townsend W; Ghesquieres H; Menne T; Porpaczy E; Fox CP; Schusterbauer C; Liu FF; Yue L; De Benedetti M; Hasskarl J Leuk Lymphoma; 2023 Mar; 64(3):573-585. PubMed ID: 36755418 [TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581 [TBL] [Abstract][Full Text] [Related]
20. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS; Lancet; 2022 Jun; 399(10343):2294-2308. PubMed ID: 35717989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]